RSP Closes Series B – Bringing Total Funding to US$28 Million

RSP Systems has completed its Series B at a total amount of US$15.5 million to accelerate regulatory approval and manufacturing of the GlucoBeam™, a novel device that offers convenient and accurate non-invasive glucose monitoring for identification of people at risk of elevated glucose. RSP Systems A/S has received an additional US$3.3 million in financing from several key investors. Series B closed at US$15.5 million, bringing RSP Systems’ total financing to approximately US$28.4 million.

We are pleased to have gained further support from investors to expedite the market launch of our device. The continuous interest from the investment community confirms the widespread need for an accurate and simple to use non-invasive glucose monitoring device improving the lives of people with diabetes

Andreas Jenne, CEO of RSP Systems

RSP’s device, GlucoBeam, uses a beam of light to painlessly and accurately measure glucose levels. It is the result of over 12 years of research and clinical development by RSP’s team of world class engineers and specialists, who have adapted well-respected Raman spectroscopy technology for daily use in a consumer device.

For more information, please contact RSP Systems’ CSO Anders Weber at


Share on facebook
Share on twitter
Share on linkedin

More news

This highly competitive grant of E2.4 million (US$2.85 million) was awarded to RSP Systems, to assist in the continued development of our …

Non-invasive monitoring of glucose successfully demonstrated in home-use We are happy to announce that our first article, entitled ‘Critical-depth Raman spectroscopy enables …

New CEO Appointed

We are delighted to announce that the Board has appointed Anders Weber CEO of RSP Systems early this month. Anders has been …